Journal article
A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer
Abstract
Cancer immunotherapies have generated remarkable clinical responses for some patients with advanced/metastatic disease, prompting exploration of rational combination therapies to bolster anti-tumor immunity in patients with limited response or those who experience tumor progression following an initial response to immunotherapy. In contrast to other tumor indications, objective response rates to single-agent PD-1/PD-L1 blockade in ovarian …
Authors
McGray AJR; Eppolito C; Miliotto A; Singel KL; Stephenson K; Lugade A; Segal BH; Keler T; Webster G; Lichty B
Journal
Cancer Immunology, Immunotherapy, Vol. 70, No. 12, pp. 3451–3460
Publisher
Springer Nature
Publication Date
December 2021
DOI
10.1007/s00262-021-02936-1
ISSN
0340-7004